 |
Claude H. Nash (born 1943) was CEO of Bloodstone Ventures plc. [1] from 2007 to 2010. From 2004 to 2006 he was vice president, research and development at the University of Maryland Biotechnology Institute. He previously cofounded, and was CEO and chairman of, ViroPharma Incorporated, a pharmaceutical company. Before founding ViroPharma, Nash was vice president of infectious disease and cancer research at the Schering-Plough Research Institute.
Nash has a B.S. in biology and chemistry from Lamar University, an M.S. in microbiology (1966) and a Ph.D. in microbial genetics and biochemistry (1969) from Colorado State University.
From 1983 to 1994 Nash served as vice president for infectious disease and oncology at Schering Plough Research Institute. During that time, he was involved in the discovery and development of numerous biological agents, antibiotics, and antifungals. Previously, he was head of biological research at Sterling Drug, head of infectious disease at SmithKline Beecham, and head of Fermentation Technology Group at Eli Lilly.
In 1997 Nash co-founded and, until 2000, was chairman, president and CEO of ViroPharma Incorporated, a pharmaceutical company based in Exton, Pennsylvania. Under his leadership ViroPharma completed an initial public offering, raised capital through public and private financing, and filed various INDs and an NDA for pleconaril to treat the common cold.
Nash currently serves or has served on the boards of directors for ViroPharma Incorporated (1997–2002), Adolor Corporation (since January 2000), Accera Pharmaceuticals, NoCopi Technologies and The Burnham Institute.
In 1984–1985 he was president of the Society for Industrial Microbiology. He received the Charles Porter Award from the Society for Industrial Microbiology and is a member of American Academy of Microbiology, Phi Kappa Phi, Sigma Xi. In 2002 he was honored as a distinguished alumnus of the College of Veterinary Medicine and Biomedical Sciences at Colorado State University.
Schering-Plough Corporation was an American pharmaceutical company. It was originally the U.S. subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization, it became an independent company. In 1971, the Schering Corporation merged with Plough, Inc. to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough with the new company taking the name of Merck & Co.
FUJIFILM Diosynth Biotechnologies, abbreviated FDB and also referred to simply as Diosynth, is a biopharmaceutical contract manufacturing organization that develops manufacturing processes and manufactures active ingredients and provides fill and finish services for pharmaceutical companies. FUJIFILM Diosynth Biotechnologies is the world's second largest contract manufacturer of biopharmaceuticals, with manufacturing facilities in Morrisville, North Carolina and College Station, Texas in the United States, Teesside, United Kingdom and Hillerød, Denmark in Europe, and recently added sites in Thousand Oaks, California and Watertown, Massachusetts. FUJIFILM Diosynth Biotechnologies operates a highly automated multipurpose manufacturing facility in College Station, Texas under the federal government's Center for Innovation in Advanced Development and Manufacturing (CIADM) program, which is the largest scale-out cell culture manufacturing facility in the United States.
Kanatzhan "Kanat" Baizakovich Alibekov, known as Kenneth "Ken" Alibek since 1992, is a Kazakh-American microbiologist, bioweaponeer, and biological warfare administrative management expert. He was the first deputy director of Biopreparat.
ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.
flanders.bio, founded in 2004, is the networking organisation for the life sciences sector in Flanders and represents and supports around 350 member companies. The key strategic objectives of flanders.bio are knowledge exchange and valorisation, human capital development, internationalization of the cluster activities and visibility, familiarization of the public with products derived from the sector and the further development of a supportive environment for the members of flanders.bio.
Pleconaril (Picovir) is an antiviral drug that was being developed by Schering-Plough for prevention of asthma exacerbations and common cold symptoms in patients exposed to picornavirus respiratory infections. Pleconaril, administered either orally or intranasally, is active against viruses in the Picornaviridae family, including Enterovirus and Rhinovirus. It has shown useful activity against the dangerous enterovirus D68.
Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.
Francesco Bellini, is an Italian-born research scientist, administrator, and Quebecer businessman.
William E. Bentley is the Robert E. Fischell Distinguished Professor of Engineering, founding Director of the Fischell Institute for Biomedical Devices, and currently the Director of the Maryland Technology Enterprise Institute in the A. James Clark School of Engineering at the University of Maryland. He was previously the Chair of the Fischell Department of Bioengineering, where he assisted in establishing the department and provided leadership that led to its nationally ranked status.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Phillip Frost is an American entrepreneur.
Michael Jaharis was an American lawyer, businessman and philanthropist. He was the founder of Kos Pharmaceuticals and Vatera Healthcare Partners LLC, and co-founder of Arisaph Pharmaceuticals.
Russell J. Howard is an Australian-born executive, entrepreneur and scientist. He was a pioneer in the fields of molecular parasitology, especially malaria, and in leading the commercialisation of one of the most important methods used widely today in molecular biology today called “DNA shuffling" or "Molecular breeding", a form of "Directed evolution".
Richard Kogan is an American businessman. He served as the president and chief executive officer of Schering-Plough from 1996 to 2003, and its chairman from 1998 to 2002.
The Department of Medical Microbiology, formerly known as the Department of Bacteriology or the Institute of Bacteriology, was a research department of the pharmaceutical company Schering AG.
Shenzhen International BT Leadership Summit is a biology-focused business conference. It is held each year in September. It is arranged by the Shenzhen Municipal People's Government. It is held at the Shenzhen Convention and Exhibition Center.
Jeffrey Leiden is an American businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.
Georg Peters was a German physician, microbiologist and university professor. From 1992 until his fatal mountain accident he headed the Institute of Medical Microbiology at the University of Münster. He was an internationally recognised expert in the field of staphylococci and the infectious diseases caused by them, to which he had devoted himself since the beginning of his scientific career.
John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.